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Streptococcus pneumoniae remains a major cause of disease and 
death in both the First World and in developing countries, and 
is the commonest cause of pneumonia, meningitis and otitis 
media. A number of host factors are known to predispose to 
pneumococcal infections including extremes of age (the very 
young and the elderly), disturbances of local immune defence 
mechanisms, such as those caused by previous viral infections 
and cigarette smoking, as well as those such as alcoholism, 
splenectomy, immunosuppression, and metabolic disorders, 
which disturb systemic immune responses.1,2 At least one 
of these factors tends to be found in patients with invasive 
pneumococcal disease. 
More recently, a number of studies of pneumococcal disease 
have investigated the pathogenesis of these infections and 
in particular the role played by the major pneumococcal 
virulence factors. Pneumolysin, a 53-kDa, thiol-activated, 
protein toxin that is produced by almost all clinically 
relevant isolates of pneumococci, is considered to be one of 
the most important virulence factors of this micro-organism 
(extensively reviewed elsewhere3-9). This toxin is able to bind 
to cholesterol in cell membranes of eukaryotic cells, where it 
oligomerises, ultimately creating trans-membrane pores. As 
a pore-forming toxin, pneumolysin is cytotoxic to a variety 
of mammalian cells, including respiratory and ependymal 
epithelium, as well as neuronal cells. In addition to its cytolytic 
domain, the pneumolysin molecule also has a complement-
activating domain that can activate complement directly in 
the absence of anti-pneumolysin antibody. Moreover, this 
toxin also has important effects on the host’s cellular and 
humoral immune system. Recently, we reviewed the potential 
role of pneumolysin in the pathogenesis and prevention 
of pneumococcal infections and the current article updates 
that manuscript,3 focusing almost exclusively on major 
developments which have occurred during the past 5 years.
The role of pneumolysin in the 
pathogenesis of pneumococcal 
infection
Pro-inflammatory activities
Pneumococcal colonisation is mostly asymptomatic, but is the 
first step in the pathogenic route of pneumococci to invasive 
disease.10  Pneumococcal disease will not occur without 
preceding nasopharyngeal colonisation with a homologous 
strain. Colonisation also plays an important part not only in 
the horizontal spread of virulent pneumococcal strains, but 
may also play a crucial role in the prevention of pneumococcal 
infections. The subject of pneumococcal colonisation has been 
extensively reviewed elsewhere.10
There is considerable understanding of the mechanisms 
by which both Gram-positive and Gram-negative micro-
organisms interact with the human host. While the immune 
response almost certainly plays an important role in preventing 
progression from colonisation by micro-organisms such as 
the pneumococcus to invasive disease, it is also recognised 
that part of the morbidity and mortality associated with 
pneumococcal disease is mediated through the host response 
to cellular components of the pneumococcus, resulting 
in excessive release of inflammatory mediators. A similar 
situation exists with other Gram-positive and Gram-negative 
pathogens. 
Pneumolysin, by virtue of cholesterol-binding, pore-forming 
activity, as well as its more-recently described interactions 
with Toll-like receptor 4 (TLR4),11 may either protect against 
or exacerbate pneumococcal infection, depending on the local 
density of toxin-producing bacteria in the airways. There are 
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currently 11 recognised members of the TLR family, these being 
the prototype pattern recognition molecules which function 
primarily as the sentinels of the innate immune system.
Exposure to small numbers of pneumococci in the airways 
results in the production of low, sub-cytolytic concentrations 
of pneumolysin, which induce production of the potent 
neutrophil chemoattractant, interleukin-8 (IL-8), by airway 
epithelium via a mechanism dependent on Ca2+ influx and 
activation of p38 mitogen-activated protein kinase and nuclear 
factor-κ B.12-14 In addition, interaction of pneumolysin with 
TLR4 on or in airway epithelium and other resident cells of the 
innate immune system in the airways, results in the production 
not only of IL-8, but also that of other proinflammatory 
cytokines such as IL-1β, IL-6, and tumour necrosis factor-α, 
all of which co-operate to facilitate transendothelial migration 
of neutrophils.11 In this setting, the consequent influx of 
neutrophils is protective, resulting in clearance of S. pneumoniae 
from the airways, and prevention of colonisation.13,14
However, hyperactivation of these same mechanisms occurs 
when colonisation of the airways with the pneumococcus is 
poorly controlled, resulting in excessive production of pro-
inflammatory cytokines and over-exuberant inflammatory 
responses. These, in turn, cause inflammation-mediated 
disruption of the bronchoalveolar-epithelial barrier, which 
favours extrapulmonary dissemination of the pneumococcus.5,15 
In addition to its pore-forming and TLR-4-mediated pro-
inflammatory activity, pneumolysin also directly activates the 
complement cascade, a strategy used by the pneumococcus 
to evade host defences, which also amplifies inflammation-
mediated tissue damage. Vulnerability to this onslaught is 
intensified by the direct, cytotoxic effects of pneumolysin on 
airway epithelium.
Cytotoxic activity 
Acute respiratory failure is a potentially serious complication 
of severe pneumococcal pneumonia. Factors that may support 
the role of pneumolysin in its pathogenesis include the fact 
that the toxin facilitates penetration of pneumococci from 
alveoli to the interstitium and then into the bloodstream, and 
that various soluble factors, predominantly pneumolysin, are 
cytotoxic to pulmonary endothelial and alveolar epithelial 
cells. Furthermore, pneumolysin, as mentioned above, has a 
wide range of pro-inflammatory activities even at sub-cytolytic 
concentrations. With these factors in mind, and having 
previously demonstrated that significant microvascular leakage 
occurs early in the course of pneumococcal infection, when 
neutrophil influx was still absent, Witzenrath and colleagues16 
studied the possible role of pneumolysin in the pathogenesis 
of this acute lung injury.  In an experimental model, they 
provided evidence for the role of pneumolysin in the acute 
lung injury due to rapid-onset action on the alveolar-capillary 
membrane and extracapillary vessels. Lung microvascular 
leakage was evident 6 hours after transnasal infection in 
mice before neutrophil influx into the lungs. Recombinant 
pneumolysin aerosolisation or infusion into the lung caused 
significant vascular leakage and pulmonary oedema, and 
pneumolysin infusion into the pulmonary circulation induced 
pulmonary hypertension, both these manifestations being 
important features of acute respiratory distress syndrome.  
In the brain, the ventricular surfaces and aqueducts are 
lined by ciliated ependymal cells which form a barrier 
between the infected CSF of patients with meningitis and the 
neuronal tissue.17 A direct link between severity of meningitis 
and pneumolysin has been shown in experimental models. 
Pneumolysin has been demonstrated in in vitro experiments 
to cause both inhibition of ependymal ciliary beat frequency, 
as well as ependymal cell disruption. Furthermore, wild-
type pneumococci, as well as pneumococci deficient in 
pneumolysin, also cause ciliary slowing. Most importantly, 
penicillin lysis of wild-type, but not pneumolysin-deficient 
pneumococci, increases the extent of ciliary inhibition. This 
effect, as well as the effect on ependymal cells of recombinant 
pneumolysin alone, is blocked by anti-pneumolysin 
monoclonal antibody. While the outcome of pneumococcal 
meningitis has been improved by the use of appropriate 
antibiotics, supplemented more recently by the addition of 
corticosteroid therapy in the form of dexamethasone, based on 
these studies it is possible that addition of anti-pneumolysin 
antibodies may further improve prognosis and warrants 
further investigation. 
Immunogenicity of pneumolysin
Pneumolysin evokes a T-cell-dependent antibody response, 
leading to the production of secretory immunoglobulin (Ig) A 
and both circulating and mucosal antibodies of the IgG class in 
animals and humans. The antibody response to pneumolysin 
in humans involves activation and proliferation of antigen-
specific CD4+ T-lymphocytes, with resultant generation of 
the cytokines interferon-gamma (IFN-γ) and tumour necrosis 
factor-α (TNF-α) by circulating lymphocytes, and IFN-γ/IL-10 
by adenoidal cells.18 The antibody response to pneumolysin 
is dependent on TLR4, compatible with a toxin-capture 
function for TLR4 expressed on antigen-presenting cells. 
Moreover, several members of the TLR family, including TLR4, 
are expressed by T-lymphocytes, and appear to function as 
co-stimulatory receptors, enhancing both proliferation and 
cytokine production.18,19
Role of pneumolysin antibodies in host 
defence in humans
Antibodies to pneumolysin have been implicated in prevention 
of both extrapulmonary dissemination of the pneumococcus, 
and nasopharyngeal carriage. In the case of the former, 
Mushner and colleagues reported that circulating antibodies to 
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pneumolysin measured in adult patients with pneumococcal 
pneumonia at the time of hospital admission were highest 
and lowest in patients with non-bacteraemic and bacteraemic 
disease respectively.20 More recently, Huo et al. reported that 
in a small group of patients with documented pneumococcal 
disease, the concentrations of circulating IgG antibodies to 
both pneumolysin and pneumococcal capsular polysaccharide 
(PPS) measured at the time of hospital admission were 
significantly lower than those of a group of age-matched 
control subjects, while IgM levels were significantly higher in 
the group of patients, suggesting that pre-existing immunity 
to these antigens may be a determinant of susceptibility to 
pneumococcal infection.21 Interestingly, in the healthy control 
subjects, salivary IgA levels to PPS, and to pneumolysin in 
particular, were significantly higher than those of IgG and IgM, 
apparently underscoring the vaccine potential of pneumolysin 
as an inducer of mucosal immunity to S. pneumoniae.
In a longitudinal study designed to investigate the 
relationship between nasopharyngeal carriage and acquisition 
of circulating IgG antibodies to both serotype-specific capsular 
polysaccharide and pneumococcal proteins, Goldblatt and 
colleagues observed that carriage of S. pneumoniae was 
accompanied by significant increases in capsule-specific IgG, as 
well as by small but significant increases in antibodies to both 
pneumolysin and pneumococcal surface adhesin A (PsaA), but 
not to pneumococcal surface protein A (PspA), with higher 
levels of anti-capsular antibodies at the outset being associated 
with a reduction in carriage.22
Using a study design apparently uncomplicated by prior 
immunisation with PPS, Holmlund et al. recently investigated 
the potential of natural, maternal antibodies to pneumococcal 
proteins to protect against pneumococcal colonisation in 
early life.23 To do this, they measured the concentrations of 
anti-pneumolysin, anti-PsaA and anti-PspA IgG antibodies in 
maternal and cord blood, as well as in serial blood specimens 
taken from infants during the 7 - 48-week period after birth, 
and correlated these with pneumococcal carriage. Interestingly, 
they found that transplacentally acquired anti-pneumolysin 
antibodies were associated with a significantly decreased 
risk of pneumococcal carriage during the first 3 months of 
life.23 The findings of a similar type of study, designed to 
investigate the relationship between nasopharyngeal carriage 
of the pneumococcus and serum and mucosal antibodies 
to pneumolysin, choline-binding protein A (CbpA), and 
PspA, were recently reported by Zhang et al. in a group of 
children aged 2 - 12 years undergoing adenoidectomy.24 These 
investigators observed that carriage rates declined with age 
in the setting of increased serum levels of antibodies to all 
three pneumococcal proteins. Anti-pneumolysin and anti-
CbpA serum and salivary IgG antibody levels were found to 
be higher in children who were culture-negative than in those 
who were colonised.24
Taken together, these various studies underscore 
the immunogenicity of pneumococcal proteins such as 
pneumolysin and CbpA, both of which are candidate 
immunogens for inclusion in pneumococcal protein vaccines.
Pneumolysin as a vaccine candidate
Notwithstanding their improved efficacy, particularly in 
children, the major limitation of pneumococcal polysaccharide-
protein conjugate vaccines is that they only elicit protective 
antibodies against the limited range of serotypes contained in 
the vaccine. The validity of this concern is underscored by the 
findings of a recent study conducted in Alaskan native children 
younger than 2 years and immunised with heptavalent 
conjugate pneumococcal vaccine, which reported that these 
children are experiencing replacement invasive pneumococcal 
disease with non-vaccine serotypes.25 Importantly, protein-
based immunisation strategies represent an attractive 
alternative, because they are likely to provide broader 
protection than the currently available conjugate vaccines. 
Pneumococcal protein vaccines may utilise individual proteins, 
or mixtures of different proteins; alternatively, individual 
pneumococcal proteins or protein cocktails could be used as 
carriers for pneumococcal polysaccharides, eliciting immunity 
against the vaccine serotypes, while protecting, albeit to a 
lesser extent, against non-vaccine serotypes. In addition to 
pneumolysin, other pneumococcal, protein virulence factors, 
CbpA, PsaA, and surface proteins A, B and C (PspA, PspB, 
PspC), have also been identified as potential candidates for 
protein vaccine development.26 
Pneumolysin represents a particularly attractive antigen 
on which to base the development of a protein vaccine 
for the following reasons: (i) it is produced by almost all 
clinically relevant strains of the pneumococcus; (ii) it induces 
T-lymphocyte-dependent immune responses resulting in 
protective, antibody-mediated systemic and mucosal immunity 
as alluded to above; and (iii) inactivated pneumolysin (toxoid) 
has been demonstrated to function not only as a protective 
immunogen per se, but also as an effective immunogenic carrier 
of pneumococcal polysaccharide in murine models of conjugate 
vaccine efficacy, being equivalent or superior to conventional 
carriers such as tetanus toxoid.27
Pneumolysin-based vaccines
Several studies using murine models of pulmonary infection 
have documented the immunogenicity and protective efficacy 
of inactivated pneumolysin, used as a mono-component 
protein vaccine, or as a carrier of polysaccharide antigens in 
conjugate vaccines.26,27 Interestingly, glycoconjugate vaccines 
consisting of pneumococcal polysaccharide coupled to 
pneumolysin have been reported to promote broader protective 
immunity in the setting of production of high avidity 
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antibodies with opsonophagocytic activity than conjugates 
which use non-pneumococcal carriers.27
In spite of its clear potential as a pneumococcal vaccine 
candidate, concerns have been expressed in respect of 
the residual toxicity of the inactivated pneumolysin 
(pneumolysoid) used as vaccine per se or as a carrier. This 
issue has been addressed recently by Kirkham et al., who 
have developed a modified pneumolysin molecule with a 
single amino acid deletion that completely attenuates pore-
forming activity.28 This modified pneumolysin not only retains 
its immunogenicity, but was also found to be protective in a 
murine model of experimental lung infection, suggesting that 
it may be an ideal contender for inclusion in pneumococcal 
protein vaccines.28
More recently, Ogunniyi et al., using an invasive disease 
model, evaluated the protective efficacy of immunisation 
of mice with pneumolysin toxoid, CbpA, PspA, and the 
pneumococcal histidine triad proteins (Pht) B and E, 
individually and in combination.29 While the protective effects 
of the individual protein vaccines were variable, immunisation 
with the combination of pneumolysoid, CbpA, and PspA, was 
found to offer the best protection.29
To our knowledge, however, no pneumococcal protein 
vaccines, either monocomponent or multicomponent, or as 
carriers in glycoconjugate vaccines, have been evaluated in 
humans.
Pneumolysin – targeted 
pharmacological strategies for the 
treatment of pneumonia
The two most promising approaches are: (i) anti-inflammatory 
agents, specifically the use of corticosteroids to attenuate 
the harmful pro-inflammatory activities of the toxin; and (ii) 
antimicrobial agents which effectively antagonise the synthesis 
of pneumolysin.
Corticosteroids
Two lines of evidence support the role of early corticosteroid 
adjunctive therapy in the management of severe pneumococcal 
disease. Firstly, several, admittedly small, studies have reported 
beneficial effects of early administration of corticosteroids 
on outcome of patients with pneumococcal meningitis or 
community-acquired pneumonia.30 Secondly, several recently 
conducted trials have demonstrated significant clinical benefit 
of low-dose corticosteroids in patients with septic shock/acute 
respiratory distress syndrome.30 Although we concluded in 
a recent review that there is currently insufficient evidence 
to enable firm recommendations to be made in respect of the 
use of corticosteroids in patients with severe pneumococcal 
disease,30 the emerging evidence with regard to corticosteroid 
use is very promising.
Antimicrobial agents
Although beta-lactam antibiotics are the agents of choice in the 
treatment of severe pneumococcal disease and are generally 
highly effective, the rate of treatment failure in severe disease 
remains unacceptably high. Recently, it has been proposed 
that combining a beta-lactam with a macrolide antimicrobial 
agent leads to a reduction in the mortality associated with 
bacteraemic pneumococcal pneumonia. Notwithstanding the 
possible involvement of the well-documented, secondary anti-
inflammatory properties of macrolides, the precise mechanisms 
which underpin the therapeutic efficacy of the beta-lactam/
macrolide combination remain to be established. The added 
benefits of the macrolide may be related to inhibition of 
the synthesis of protein virulence factors, particularly 
pneumolysin, which is released during beta-lactam-mediated 
disintegration of the pneumococcus.
We have recently reported that the production of 
pneumolysin is attenuated by exposure of the pneumococcus 
to sub-inhibitory concentrations of the macrolide, 
clarithromycin.31 Interestingly, clarithromycin-mediated 
inhibition of the production of pneumolysin was observed not 
only with macrolide-susceptible strains of the pneumococcus, 
but also with macrolide-resistant strains which harboured 
either the ribosomal methylase (erm gene)- or efflux pump 
(mef gene)-based mechanisms of macrolide resistance.31 These 
observations are in agreement with those of Fukuda et al., who 
reported that clarithromycin and azithromycin inhibited the 
production of pneumolysin by macrolide-resistant strains of 
S. pneumoniae in vitro, as well as in the lungs of experimentally 
infected mice.32 In a recent study, we observed that macrolides 
(clarithromycin, erythromycin), azalides (azithromycin), 
ketolides (telithromycin), and lincosamides (clindamycin), 
at sub-inhibitory concentrations, effectively attenuate the 
production of pneumolysin by both macrolide-susceptible 
and macrolide-resistant strains of the pneumococcus. Other 
types of antimicrobial agent commonly used in the treatment 
of infections caused by this microbial pathogen, including 
amoxicillin, ceftriaxone, ciprofloxacin, moxifloxacin, and 
tobramycin did not affect pneumolysin production.33
These apparently selective inhibitory effects of macrolides on 
the production of pneumolysin by both macrolide-susceptible 
and macrolide-resistant strains of the pneumococcus may 
provide an explanation for the benefit of combining these 
agents with beta-lactams on the outcome of bacteraemic 
pneumococcal pneumonia.
Conclusions
Infections with S. pneumoniae continue to be a major cause of 
patient morbidity and mortality worldwide. Several recent 
studies have underscored the involvement of pneumolysin, 
one of the major virulence factors of the organism, in the 
pathogenesis of severe infections caused by the pneumococcus. 
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In addition to playing a significant role in the disease process, 
the toxin is also highly immunogenic and represents not 
only an ideal protein carrier for a future polysaccharide 
conjugate vaccine, but can also serve as a major component 
of a pneumococcal protein vaccine. Furthermore, strategies 
which improve the outcome of severely ill patients with 
pneumococcal infection, such as the use of corticosteroids, or 
the addition of a macrolide to standard beta-lactam therapy 
appear to target pneumolysin, by respective attenuation of its 
pro-inflammatory activities, or by preventing its synthesis. 
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